A follow-up case-control association study of tractable (druggable) genes in recurrent major depression

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 156, Issue 6, 2011, Pages 640-650

  Schosser, A ^a,b   Gaysina, D ^a   Cohen Woods, S ^a   Domenici, E ^c,d   Perry, J ^c   Tozzi, F ^c   Korszun, A ^e   Gunasinghe, C ^a   Gray, J ^a   Jones, L ^f   Binder, E B ^g   Holsboer, F ^g   Craddock, N ^h   Owen, M J ^h   Craig, I W ^a   Farmer, A E ^a   Muglia, P ^c,i   Mcguffin, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GSK   (Italy)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

Association; Candidate genes; Case control study; Depression; Genetics

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR D3; MEMBRANE PROTEIN; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE 2A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SOLUTE CARRIER FAMILY 4 MEMBER 10; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 80;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENOTYPE; HAPLOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHENOTYPE; PRIORITY JOURNAL; RECURRENT MAJOR DEPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; GREAT BRITAIN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE;

EID: 80051556334     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31204     Document Type: Article

References (49)

1. Als TD, Dahl HA, Flint TJ, Wang AG, Vang M, Mors O, et al. 2004. Possible evidence for a common risk locus for bipolar affective disorder and schizophrenia on chromosome 4p16 in patients from the Faroe Islands. Mol Psychiatry 9: 93-98.
2. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2): 263-265.
3. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ. 2002. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder. World J Biol Psychiatry 3: 5-43.
4. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. 2001. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
5. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai P, Bogerts B. 1998. Nitric oxide synthase-containing neurons in the human hypothalamus: Reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83: 867-875.
6. Black MD, Selk DE, Hitchcock JM, Wettstein JG, Sorensen SM. 1999. On the effect of neonatal nitric oxide synthase inhibition in rats: A potential neurodevelopmental model of schizophrenia. Neuropharmacology 38: 1299-1306.
7. Blackwood DH, He L, Morris SW, McLean A, Whitton C, Thomson M, et al. 1996. A locus for bipolar affective disorder on chromosome 4p. Nat Genet 12: 427-430.
8. Brown GC, Bal-Price A. 2003. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 27: 325-355.
9. Celik C. 2003. Computer assisted personal interviewing application for the Schedules for Clinical Assessment in Neuropsychiatry Version 2.1 and diagnostic algorithms for WHO ICD10 chapter V DCR and for statistical manual IV. Release 1. Ed. 1. 0. 3. 5. Win 9x NT. Geneva: World Health Organization.
10. Christoforou A, Le Hellard S, Thomson PA, Morris SW, Tenesa A, Pickard BS, et al. 2007. Association analysis of the chromosome 4p15-p16 candidate region for bipolar disorder and schizophrenia. Mol Psychiatry 12: 1011-1025.
11. Daban C, Vieta E, Mackin P, Young AH. 2005. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 28: 469-480.
12. Detera-Wadleigh SD, Badner JA, Berrettini WH, Yoshikawa T, Goldin LR, Turner G, et al. 1999. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci USA 96: 5604-5609.
13. Dudbridge F. 2003. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25(2): 115-121.
14. Dupont WD, Plummer WD, Jr. 1990. Power and sample size calculations. A review and computer program. Control Clin Trials 11(2): 116-128.
15. Elgün S, Keskinege A, Kumbasar H. 1999. Dipeptidyl peptidase IV and adenosine deaminase activity. Decrease in depression. Psychoneuroendocrinology 24(8): 823-832.
16. Farmer A, Breen G, Brewster S, Craddock N, Gill M, Korszun A, et al. 2004. The Depression Network (DeNT) Study: Methodology and sociodemographic characteristics of the first 470 affected sibling pairs from a large multi-site linkage genetic study. BMC Psychiatry 4: 42.
17. Farmer A, Korszun A, Owen MJ, Craddock N, Jones L, Jones I, et al. 2008. Medical disorders in people with recurrent depression. Br J Psychiatry 192: 351-355.
18. Freeman B, Powell J, Ball D, Hill L, Craig I, Plomin R. 1997. DNA by mail: An inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations. Behav Genet 27: 251-257.
19. Freeman B, Smith N, Curtis C, Huckett L, Mill J, Craig IW. 2003. DNA from buccal swabs recruited by mail: Evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behav Genet 33: 67-72.
20. Frerker N, Raber K, Bode F, Skripuletz T, Nave H, Klemann C, et al. 2009. Phenotyping of congenic depeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions. Clin Chem Lab Med 47: 275-287.
21. Herken H, Uz E, Ozyurt H, Akyol O. 2001. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 52: 289-290.
22. Hettma JM. 2008. What is the genetic relationship between anxiety and depression? Am J Med Genet Part C 148C: 140-146.
23. Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF. 2000. A guardian angel: The involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci (Lond) 99(2): 93-104. Review.
24. Itokawa M, Kasuga T, Yoshikawa T, Matsushita M. 2004. Identification of a male schizophrenic patient carrying a de novo balanced translocation, t(4;13)(p16.1;q21.31). Psychiatry Clin Neurosci 58: 333-337.
25. Karl T, Hoffmann T, Pabst R, von Hörsten S. 2003. Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiol Behav 80: 123-134.
26. Katon WJ. 2008. The comorbidity of diabetes mellitus and depression. Am J Med 121: S8-S15.
27. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RMA. 1986. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: A prospective follow-up. Am J Psychiatry 143: 24-28.
28. Lambeir AM, Durinx C, Scharpé S, De Meester I. 2003. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40(3): 209-294.
29. Le Hellard S, Lee AJ, Underwood S, Thomson PA, Morris SW, Torrance HS, et al. 2007. Haplotype analysis and a novel allele-sharing method refines a chromosome 4p locus linked to bipolar affective disorder. Biol Psychiatry 61: 797-805.
30. Maes M, De Meester I, Vanhoof G, Scharpé S, Bosmans E, Vandervorst C, et al. 1991. Decreased serum dipeptidyl peptidase IV activity in major depression. Biol Psychiatry 30(6): 577-586.
31. McGuffin P, Katz R, Aldrich J. 1986. Past and present state examination: The assessment of 'lifetime ever' psychopathology. Psychol Med 16(2): 461-465.
32. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD. 1999. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 156: 1000-1006.
33. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, et al. 2010. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry 15: 589-601.
34. Papageorgious C, Grapsa E, Christodoulou NG, Zerefos N, Stamatelopoulos S, Christodoulou GN. 2001. Association of serum nitric oxide levels with depressive symptoms: A study with end-stage renal failure patients. Psychother Psychosom 70: 216-220.
35. Pariante CM, Lightman SL. 2008. The HPA axis in major depression: Classical theories and new developments. Trends Neurosci 31: 464-468.
36. Roses AD, Burns DK, Chissoe S, Middleton L, St Jean P. 2005. Disease-specific target selection: A critical first step down the right road. Drug Discov Today 10: 177-189. Review.
37. Savas HA, Herken H, Yurekli M, Uz E, Tutkun H, Zoroglu SS, et al. 2002. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 45: 57-61.
38. Schosser A, Gaysina D, Cohen-Woods S, Chow PC, Martucci L, Craddock N, et al. 2010. Association of DISC1 and TSNAX genes and affective disorders in the depression case-control (DeCC) and bipolar affective case-control (BACCS) studies. Mol Psychiatry 15(8): 844-849.
39. Schulman H. 1997. Nitric oxide: A spatial second messenger. Mol Psychiatry 2: 296-299.
40. Sham PC, Sterne A, Purcell S, Cherny S, Webster M, Rijsdijk F, et al. 2000. GENESIS: Creating a composite index of the vulnerability to anxiety and depression in a community-based sample of siblings. Twin Res 3: 316-322.
41. Tashiro A, Hongo M, Ota R, Utsumi A, Imai T. 1997. Hyper-insulin response in a patient with depression. Changes in insulin resistance during recovery from depression. Diabetes Care 20: 1924-1925.
42. Taylor JD, Briley D, Nguyen Q, Lond K, Iannone MA, Li MS, et al. 2001. Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques 30(3): 661-666, 668-669.
43. Visscher PM, Haley CS, Heath SC, Muir WJ, Blackwood DH. 1999. Detecting QTLs for uni- and bipolar disorder using a variance component method. Psychiatr Genet 9: 75-84.
44. Waraich P, Goldner EM, Somers JM, Hsu L. 2004. Prevalence and incidence studies of mood disorders: A systematic review of the literature. Can J Psychiatry 49: 124-138.
45. Wing J. 1990. SCAN-Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1(900): 85-90.
46. Winokur A, Maislin G, Phillips JL, Amsterdam JD. 1988. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 145: 325-330.
47. Wittchen HU, Hoefler M, Gander F, Pfister H, Storz S, Ustun TB, et al. 1999a. Screening for mental disorders: Performance of the Composite International Diagnostic-Screener (CID-S). Int J Methods Psychiatr Res 8: 59-70.
48. Wittchen HU, Lieb R, Wunderlich U, Schuster P. 1999b. Comorbidity in primary care: Presentation and consequences. J Clin Psychiatry 60(7): 29-36.
49. Wittchen HU. 2000. Epidemiology of affective disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N, editors. Contemporary psychiatry, (Vol 3). Springer: Heidelberg. pp. 231-241.